| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8775498 | Urology | 2018 | 24 Pages |
Abstract
PSA testing and prostate biopsy rates decreased significantly between 2011 and 2014. The rate of PSA testing was not differentially affected by ACO participation. Conversely, there was an increase in the rate of prostate biopsy among patients of ACO-aligned physicians. ACOs did not accelerate deimplementation of PSA testing for eligible Medicare beneficiaries without prostate cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Amy N. Luckenbaugh, Brent K. Hollenbeck, Samuel R. Kaufman, Phyllis Yan, Lindsey A. Herrel, Ted A. Skolarus, Edward C. Norton, Florian R. Schroeck, Bruce L. Jacobs, David C. Miller, John M. Hollingsworth, Vahakn B. Shahinian, Tudor Borza,